Patents by Inventor Agamemnon Epenetos

Agamemnon Epenetos has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Peptide conjugates
    Patent number: 11357863
    Abstract: The present invention provides peptide conjugates capable of translocating across the cytoplasmic membrane of a mammalian cell and inhibiting the Notch signalling pathway. Peptide conjugates, compositions and methods of the invention are useful for targeting chemo-resistant cancer stem cells.
    Type: Grant
    Filed: August 24, 2018
    Date of Patent: June 14, 2022
    Assignee: Anastasis Biotec Limited
    Inventor: Agamemnon Epenetos
  • Conjugate comprising P21 protein for the treatment of cancer
    Patent number: 10259852
    Abstract: The P21 protein is used as a medicament in the treatment of cancer, conjugate comprises a first region comprising the P21 protein, or a homolog functional fragment thereof; and a second region comprising a translocation factor.
    Type: Grant
    Filed: September 22, 2015
    Date of Patent: April 16, 2019
    Assignee: Anastasis Biotec Limited
    Inventors: Agamemnon Epenetos, Christina Kousparou
  • CONJUGATE COMPRISING P21 PROTEIN FOR THE TREATMENT OF CANCER
    Publication number: 20160068582
    Abstract: The P21 protein is used as a medicament in the treatment of cancer, conjugate comprises a first region comprising the P21 protein, or a homologue functional fragment thereof; and a second region comprising a translocation factor.
    Type: Application
    Filed: September 22, 2015
    Publication date: March 10, 2016
    Inventors: Agamemnon Epenetos, Christina Kousparou
  • Conjugate comprising P21 protein for the treatment of cancer
    Patent number: 9145446
    Abstract: The P21 protein is used as a medicament in the treatment of cancer. A conjugate comprises a first region comprising the P21 protein, or a homologue or functional fragment thereof; and a second region comprising a translocation factor.
    Type: Grant
    Filed: October 29, 2009
    Date of Patent: September 29, 2015
    Assignee: Trojan Technologies, Ltd.
    Inventors: Agamemnon Epenetos, Christina Kousparou
  • CONJUGATE COMPRISING P21 PROTEIN FOR THE TREATMENT OF CANCER
    Publication number: 20110021441
    Abstract: The P21 protein is used as a medicament in the treatment of cancer. A conjugate comprises a first region comprising the P21 protein, or a homologue or functional fragment thereof; and a second region comprising a translocation factor.
    Type: Application
    Filed: October 29, 2009
    Publication date: January 27, 2011
    Applicant: Trojan Technologies Limited
    Inventors: Agamemnon Epenetos, Christina Kousparou
  • Biological Materials and Uses Thereof
    Publication number: 20100069321
    Abstract: The invention relates to the modification of proteins to improve their, biochemical, immunological or biophysical properties, in turn leading to such proteins having increased diagnostic, biotechnological or therapeutic benefit. In particular the invention relates to polysialylation of proteins or conjugates of proteins. There is also provided, nucleotide sequences and expression vectors encoding, host cells expressing, compositions comprising and uses of the polysialylated molecules of the invention.
    Type: Application
    Filed: August 31, 2007
    Publication date: March 18, 2010
    Applicant: IMPERIAL INNOVATIONS LIMITED
    Inventors: Mahendra Deonarain, Agamemnon Epenetos, Anthony Constantinou
  • Conjugate Comprising P21 Protein for the Treatment of Cancer
    Publication number: 20080287357
    Abstract: The P21 protein is used as a medicament in the treatment of cancer. A conjugate comprises a first region comprising the P21 protein, or a homologue or functional fragment thereof; and a second region comprising a translocation factor.
    Type: Application
    Filed: April 18, 2006
    Publication date: November 20, 2008
    Applicant: Trojan Technologies Limited
    Inventors: Agamemnon Epenetos, Christina Kousparou
  • Potent cytotoxicity and inhibition of pan-cell cycle progression by an alkylating anthraquinone
    Publication number: 20070208085
    Abstract: The present invention generally relates to chemotherapeutic treatment of proliferative disorders, such as cancer. The invention more specifically relates to inhibition of pan-cell cycle progression with alkylating anthraquinones, which may inhibit mitotic commitment, lead to limited expression of G2 arrest and force cells to enter polyploidy via an aberrant mitosis. The methods of the invention are particularly useful in the treatment of chemotherapy-resistant cancers.
    Type: Application
    Filed: January 17, 2007
    Publication date: September 6, 2007
    Applicant: SOMANTA LIMITED
    Inventors: Agamemnon Epenetos, Klaus Pors, Paul Smith, Laurence Patterson